Immunotherapy in Breast Cancer: When, How, and What Challenges?
Breast Cancer (BC) is the second most frequent cause of cancer death among women worldwide and, although there have been significant advances in BC therapies, a significant percentage of patients develop metastasis and disease recurrence. Since BC was demonstrated to be an immunogenic tumor, immunot...
Guardado en:
Autores principales: | Beatriz Henriques, Fernando Mendes, Diana Martins |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c4eda406d474bdaad2bdcd7ba989998 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021) -
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
por: Mina LA, et al.
Publicado: (2020) -
Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Mai F. Tolba, et al.
Publicado: (2021) -
Histamine in cancer immunology and immunotherapy. Current status and new perspectives
por: María de la Paz Sarasola, et al.
Publicado: (2021) -
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub NM, et al.
Publicado: (2019)